EMulate is a clinical-stage therapeutic device company utilizing its patented RFE technology to provide effective treatments for numerous unmet medical needs
Our CEO, Chris Rivera, recently spoke with @PM360online about the leadership lessons he’s learned throughout his career and what he believes sets up a company for success. Click here to read the article: https://t.co/2Ci1Ajk0RS
Our CEO, Chris Rivera and VP, Preclinical Development, Xavier Figueroa, Ph.D. spoke with Pharma’s Almanac about our disruptive technology and how it may help usher in a true digital transformation in healthcare. Read more on what they had to say here: https://t.co/sU1Png70fP
Our CEO, Chris Rivera, spoke with @LongevityTech to discuss EMulate’s #technology and how it emulates drugs without using harsh chemicals, as well as several advantages that may help you live a healthier, longer life. Click here to read more: https://t.co/gA0uti7j66
Recently, we announced the publication of positive preclinical data evaluating the use of EMulate’s wearable device that uses WAV files to deliver low to ultra-low radio frequency energy in validated murine models of pain. More on the data here: https://t.co/YX5xsrMPRl
EMulate Therapeutics today announced the formation of a new technology advisory committee that will bring expertise across multiple disciplines to facilitate company growth and innovation. To learn more details on the committee, click here: https://t.co/yi77dfhqeI
EMulate Therapeutics was recently named a top 10 emerging company at the forefront of providing therapeutics services in The Life Sciences Review Magazine (@lifesciencesrev), August 2022 Therapeutics Edition. To view the August edition, click here: https://t.co/6cZSrIC3nv
We are now on Twitter! EMulate Therapeutics is a clinical-stage therapeutic device company, utilizing radio frequency energy (RFE) technology to treat unmet medical needs. Follow us for corporate and clinical updates, and visit our website to learn more: https://t.co/3YEcCO6wrm